ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal...
AUM302 has potential to be the first multi-kinase inhibitor class of drug in NeuroblastomaSINGAPORE and BETHESDA, Md., Nov. 30, 2022...
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy...
Recent achievements showcase company’s leadership as CRO Partner and Employer of Choice in the Asia/Pacific regionBOSTON and DURHAM, N.C., Nov. 29,...
Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic breast cancer who have progressed...
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical...
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents...
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of...
INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD conference in San Francisco November...
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics...
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal sprayWARREN, N.J., Nov. 29,...
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi™NEW...
Company is Opting to Increase Study Size to 400 due to Fast Enrollment PaceCARSON CITY, Nev., Nov. 29, 2022 (GLOBE...
SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumorsPreclinical efficacy and tolerability studies...
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov....
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host...
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant...
– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell...
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company...
